APAnton PozniakMD, FRCPVideoHIVGlobal HIV Clinical Forum 2017Optimizing Clinical Utility of Integrase Inhibitors | Anton Pozniak, MD, FRCPView Video
PCPedro CahnMD, PhDVideoHIVGlobal HIV Clinical Forum 2017Clinical Case -Reduced Drug Regimen | Pedro Cahn, MD, PhDView Video
PCPep CollMD, MSVideoHIVGlobal HIV Clinical Forum 2017The Role of Integrase Inhibitors during HIV prevention | Pep Coll, MDView Video
SWSharon WalmsleyCM, MD, FRCPCVideoHIVGlobal HIV Clinical Forum 2017https://academicmedicaleducation.com/meeting/global-hiv-clinical-forum-2017/video/clinical-pharmacology-related-considerations-davidView Video
DBDavid BackPhDVideoHIVGlobal HIV Clinical Forum 2017Clinical Pharmacology related considerations | David Back, PhDView Video
VideoHIVGlobal HIV Clinical Forum 2017Potential role of Integrase Inhibitors in resource-limited settings | Gary Maartens, MDView Video
VideoHIVGlobal HIV Clinical Forum 2017Clinical Case - Transmitted/Acquired Resistance Related | Michelle Moorhouse, MBBChView Video
VideoViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2017Navigating NASH biomarkers: From discovery to clinical practice | John Sninsky, PhDView Video
ASArun SanyalMD, MBBSVideoViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2017Integrated assessment of diabetes, cardiovascular and liver risks and its potential application in the clinical management of NAFLD | Arun Sanyal, MD, MBBSView Video
VideoViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2017Big data vs. the individual liver - regulatory perspective | Robert Schuck, PharmD, PhDView Video
VideoViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2017Principles of kinetic measures | Greg Everson, MD, FACPView Video
VideoViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2017Breath tests | Shadab Siddiqui, MDView Video
